Amyndas is a fast-developing innovator and emerging leader in the field of “complement therapeutics,” with a compelling investment proposition, a highly promising pipeline and attractive M&A/licensing opportunities.
The company is committed to developing the most advanced therapies to treat inflammatory disorders, in particular orphan diseases and conditions representing areas of unmet medical need for which patients need better and safer therapies. It has programs in Transplantation, the rare hemolytic disease Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 glomerulonephritis, Periodontitis, Age-Related Macular Degeneration, Hemodialysis and Ischemia/Reperfusion Injuries.
Amyndas is founded on the world-class science and expertise of Dr. John Lambris, a world leader in complement research, with 40 years experience in the complement field, over 480 scientific publications in top journals and the inventor of a broad IP portfolio. It is also supported by an international network of scientific, clinical and industry experts with strong experience in the clinical development process and a proven track record of bringing compounds from discovery through to the clinic.